The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Moshe Talpaz, Susan O'Brien, Francis Giles, Mary Beth Rios, Jianqin Shan, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-α failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3-4) fibrosis was observed in 67 patients (61%). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58%; P=0.45) compared with those with mild-moderate fibrosis. The estimated 4 year survival rates (80 vs. 88%; P=0.27) and failure-free survival rates (69 vs. 77%; P=0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy.

Original languageEnglish (US)
Pages (from-to)993-997
Number of pages5
JournalLeukemia and Lymphoma
Volume46
Issue number7
DOIs
StatePublished - Jul 25 2005
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fibrosis
Reticulin
Bone Marrow
Survival Rate
Leukemia, Myeloid, Chronic Phase
Therapeutics
Philadelphia Chromosome
Cytogenetics
Interferons
Coloring Agents
Imatinib Mesylate

Keywords

  • Chronic myelogenous leukemia (CML)
  • Imatinib mesylate
  • Marrow fibrosis
  • Philadelphia chromosome-positive chronic phase
  • Prognostic significance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. / Kantarjian, Hagop M.; Bueso-Ramos, Carlos E.; Talpaz, Moshe; O'Brien, Susan; Giles, Francis; Rios, Mary Beth; Shan, Jianqin; Cortes, Jorge.

In: Leukemia and Lymphoma, Vol. 46, No. 7, 25.07.2005, p. 993-997.

Research output: Contribution to journalArticle

Kantarjian, Hagop M. ; Bueso-Ramos, Carlos E. ; Talpaz, Moshe ; O'Brien, Susan ; Giles, Francis ; Rios, Mary Beth ; Shan, Jianqin ; Cortes, Jorge. / The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 7. pp. 993-997.
@article{98943af4c76f427aae5abbc2f29a52f2,
title = "The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy",
abstract = "One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-α failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3-4) fibrosis was observed in 67 patients (61{\%}). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58{\%}; P=0.45) compared with those with mild-moderate fibrosis. The estimated 4 year survival rates (80 vs. 88{\%}; P=0.27) and failure-free survival rates (69 vs. 77{\%}; P=0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy.",
keywords = "Chronic myelogenous leukemia (CML), Imatinib mesylate, Marrow fibrosis, Philadelphia chromosome-positive chronic phase, Prognostic significance",
author = "Kantarjian, {Hagop M.} and Bueso-Ramos, {Carlos E.} and Moshe Talpaz and Susan O'Brien and Francis Giles and Rios, {Mary Beth} and Jianqin Shan and Jorge Cortes",
year = "2005",
month = "7",
day = "25",
doi = "10.1080/10428190500097581",
language = "English (US)",
volume = "46",
pages = "993--997",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

AU - Kantarjian, Hagop M.

AU - Bueso-Ramos, Carlos E.

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Giles, Francis

AU - Rios, Mary Beth

AU - Shan, Jianqin

AU - Cortes, Jorge

PY - 2005/7/25

Y1 - 2005/7/25

N2 - One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-α failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3-4) fibrosis was observed in 67 patients (61%). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58%; P=0.45) compared with those with mild-moderate fibrosis. The estimated 4 year survival rates (80 vs. 88%; P=0.27) and failure-free survival rates (69 vs. 77%; P=0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy.

AB - One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-α failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3-4) fibrosis was observed in 67 patients (61%). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58%; P=0.45) compared with those with mild-moderate fibrosis. The estimated 4 year survival rates (80 vs. 88%; P=0.27) and failure-free survival rates (69 vs. 77%; P=0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy.

KW - Chronic myelogenous leukemia (CML)

KW - Imatinib mesylate

KW - Marrow fibrosis

KW - Philadelphia chromosome-positive chronic phase

KW - Prognostic significance

UR - http://www.scopus.com/inward/record.url?scp=22144465244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144465244&partnerID=8YFLogxK

U2 - 10.1080/10428190500097581

DO - 10.1080/10428190500097581

M3 - Article

C2 - 16019549

AN - SCOPUS:22144465244

VL - 46

SP - 993

EP - 997

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -